KR101911109B1 - 신규 제약 조성물 - Google Patents

신규 제약 조성물 Download PDF

Info

Publication number: KR101911109B1
Authority: KR; South Korea
Prior art keywords: compound; suitably; tablets; drug; amount
Prior art date: 2010-12-20

Application number

KR1020137019029A

Other languages

English (en)

Korean (ko)

Other versions

KR20130130028A (ko

Inventor

더글라스 제이. 드마리니

넉디에프 티. 러

프란시스코 엔리케스

리홍 왕

Original Assignee

노파르티스 아게

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-12-20

Filing date

2011-12-20

Publication date

2018-10-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46314827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101911109(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-12-20 Application filed by 노파르티스 아게 filed Critical 노파르티스 아게

2013-11-29 Publication of KR20130130028A publication Critical patent/KR20130130028A/ko

2018-10-23 Application granted granted Critical

2018-10-23 Publication of KR101911109B1 publication Critical patent/KR101911109B1/ko

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Inorganic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

KR1020137019029A 2010-12-20 2011-12-20 신규 제약 조성물 KR101911109B1 (ko)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201061424967P	2010-12-20	2010-12-20
US61/424,967		2010-12-20
PCT/US2011/066021 WO2012088033A2 (en)	2010-12-20	2011-12-20	Novel pharmaceutical composition

Publications (2)

Publication Number	Publication Date
KR20130130028A KR20130130028A (ko)	2013-11-29
KR101911109B1 true KR101911109B1 (ko)	2018-10-23

Family

ID=46314827

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
KR1020137019029A KR101911109B1 (ko)	2010-12-20	2011-12-20	신규 제약 조성물

Country Status (37)

Country	Link
US (5)	US8580304B2 (sr)
EP (4)	EP4159204B1 (sr)
JP (2)	JP6126014B2 (sr)
KR (1)	KR101911109B1 (sr)
CN (1)	CN103998041B (sr)
AR (2)	AR084102A1 (sr)
AU (1)	AU2011349422B2 (sr)
BR (1)	BR112013015602B1 (sr)
CA (1)	CA2822701C (sr)
CL (1)	CL2013001779A1 (sr)
CR (1)	CR20130352A (sr)
CY (1)	CY1123376T1 (sr)
DK (3)	DK2654736T3 (sr)
DO (1)	DOP2013000138A (sr)
EA (1)	EA025198B1 (sr)
ES (3)	ES2820536T3 (sr)
FI (2)	FI4159205T3 (sr)
HR (3)	HRP20240563T1 (sr)
HU (3)	HUE066526T2 (sr)
IL (1)	IL226855A (sr)
JO (1)	JO3594B1 (sr)
LT (3)	LT2654736T (sr)
MA (1)	MA34883B1 (sr)
MX (1)	MX2013007073A (sr)
MY (1)	MY170501A (sr)
NZ (1)	NZ612157A (sr)
PE (1)	PE20140040A1 (sr)
PL (3)	PL4159205T3 (sr)
PT (3)	PT2654736T (sr)
RS (2)	RS65496B1 (sr)
SG (1)	SG191054A1 (sr)
SI (3)	SI2654736T1 (sr)
TW (1)	TWI505828B (sr)
UA (1)	UA113158C2 (sr)
UY (1)	UY33818A (sr)
WO (1)	WO2012088033A2 (sr)
ZA (1)	ZA201304189B (sr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ744862A (en)	2012-08-17	2019-06-28	Hoffmann La Roche	Combination therapies for melanoma comprising administering cobimetinib and vemurafenib
KR102206432B1 (ko) *	2012-11-30	2021-01-22	노파르티스 아게	신규 제약 조성물
WO2015019125A1 (en) *	2013-08-05	2015-02-12	Societe De Developpement Et De Recherche Industrielle	Molecular targets for the treatment of wounds, in particular chronic wounds
CN103819471A (zh) *	2013-11-25	2014-05-28	镇江圣安医药有限公司	吡啶并(4,3-d)嘧啶-1（2H）-基苯基乙酰胺的衍生物及其应用
WO2015081566A1 (zh) *	2013-12-06	2015-06-11	杭州普晒医药科技有限公司	曲美替尼及其溶剂化物的晶型、其制备方法、含有它们的药物组合物及其用途
EP2913048A1 (en) *	2014-02-27	2015-09-02	ratiopharm GmbH	Pharmaceutical composition comprising trametinib
KR101545268B1 (ko)	2015-02-05	2015-08-20	보령제약 주식회사	정제 및 이의 제조방법
WO2016126012A1 (en) *	2015-02-05	2016-08-11	Boryung Pharmaceutical Co., Ltd	Tablet and method of preparing the same
US20170020880A1 (en) *	2015-07-22	2017-01-26	Hetero Research Foundation	Pharmaceutical compositions of trametinib
CA3032233C (en)	2016-08-10	2021-09-14	F. Hoffmann-La Roche Ag	Pharmaceutical compositions comprising akt protein kinase inhibitors
RU2627692C1 (ru) *	2016-10-10	2017-08-10	Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм")	N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2
US10709699B2 (en)	2016-11-25	2020-07-14	Jiangsu Hengrui Medicine Co., Ltd.	Pyridone derivative pharmaceutical composition and preparation method thereof
KR20240032157A (ko)	2017-05-02	2024-03-08	노파르티스 아게	병용 요법
AU2020311942A1 (en)	2019-07-11	2022-02-24	Praxis Precision Medicines, Inc.	Formulations of T-type calcium channel modulators and methods of use thereof
EP4007585A4 (en)	2019-08-02	2023-11-08	OneHealthCompany, Inc.	TREATMENT OF CANCER IN DOGS
RU2749719C1 (ru) *	2020-10-08	2021-06-16	Нестерук Владимир Викторович	Препарат для лечения анемии, связанной с хроническим заболеванием почек, и способ его получения
EP4444299A1 (en)	2021-12-06	2024-10-16	My Personal Therapeutics Ltd	A combination treatment for cancer
WO2024171019A1 (en) *	2023-02-13	2024-08-22	Alembic Pharmaceuticals Limited	Pharmaceutical composition of trametinib and process of preparation thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4727077A (en)	1985-02-20	1988-02-23	Ishihara Sangyo Kaisha Ltd.	Benzoyl urea compounds, process for their production, and antitumorous compositions containing them
JPS61205257A (ja) *	1985-03-08	1986-09-11	Ishihara Sangyo Kaisha Ltd	ベンゾイルウレア系化合物、その製法及びそれを含有する抗ガン剤
US5559235A (en)	1991-10-29	1996-09-24	Glaxo Wellcome Inc.	Water soluble camptothecin derivatives
US5342947A (en)	1992-10-09	1994-08-30	Glaxo Inc.	Preparation of water soluble camptothecin derivatives
US5681835A (en)	1994-04-25	1997-10-28	Glaxo Wellcome Inc.	Non-steroidal ligands for the estrogen receptor
US5491237A (en)	1994-05-03	1996-02-13	Glaxo Wellcome Inc.	Intermediates in pharmaceutical camptothecin preparation
GB9716557D0 (en)	1997-08-06	1997-10-08	Glaxo Group Ltd	Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6825180B2 (en)	2001-05-18	2004-11-30	Cell Therapeutics, Inc.	Pyridopyrimidine compounds and their uses
KR100883289B1 (ko) *	2004-06-11	2009-02-11	니뽄 다바코 산교 가부시키가이샤	암 치료용5-아미노-2,4,7-트리옥소-3,4,7,8-테트라히드로-2ｈ-피리도[2,3-ｄ]피리미딘 유도체 및 관련 화합물
US7378423B2 (en) *	2004-06-11	2008-05-27	Japan Tobacco Inc.	Pyrimidine compound and medical use thereof
US7955622B2 (en) *	2006-10-13	2011-06-07	Actavis Group Ptc Hf	Controlled-release galantamine formulations
US20080145433A1 (en) *	2006-11-09	2008-06-19	Gilead Colorado, Inc.	Darusentan oral dosage form
JO2985B1 (ar) *	2006-12-20	2016-09-05	Takeda Pharmaceuticals Co	مثبطات كينازmapk/erk
UY30892A1 (es)	2007-02-07	2008-09-02	Smithkline Beckman Corp	Inhibidores de la actividad akt
ECSP077628A (es)	2007-05-03	2008-12-30	Smithkline Beechman Corp	Nueva composición farmacéutica
EP2175885B1 (en) *	2007-07-30	2016-10-12	Ardea Biosciences, Inc.	Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
BRPI0817946A2 (pt) *	2007-09-25	2015-05-05	Teva Pharma	Composições de imatinibe estável
KR20110031370A (ko)	2008-07-08	2011-03-25	베타 파마, 인크.	염산 ｉｃｏｔｉｎｉｂ, 합성, 결정형, 약학적 조성물 및 이의 사용
BR112012006693A2 (pt)	2009-09-23	2015-09-08	Glaxosmithkline Llc	combinação
CN102762098B (zh)	2009-09-23	2015-10-14	葛兰素史密斯克莱有限责任公司	组合
US20120245180A1 (en) *	2009-09-28	2012-09-27	Glaxosmithkline Llc	Combination
JP5718929B2 (ja)	2009-10-16	2015-05-13	グラクソスミスクラインエルエルシー	組合せ物
CN102724979A (zh)	2009-11-17	2012-10-10	葛兰素史密斯克莱有限责任公司	组合
WO2012027438A1 (en) *	2010-08-26	2012-03-01	Glaxosmithkline Llc	Pharmaceutical combination of a vegfr inhibitor and a mek inhibitor useful for treating cancer
US8977217B1 (en)	2013-02-20	2015-03-10	Triquint Semiconductor, Inc.	Switching device with negative bias circuit

2011
- 2011-12-16 TW TW100146692A patent/TWI505828B/zh active
- 2011-12-18 JO JOP/2011/0385A patent/JO3594B1/ar active
- 2011-12-19 AR ARP110104773A patent/AR084102A1/es not_active Application Discontinuation
- 2011-12-19 UY UY0001033818A patent/UY33818A/es active IP Right Grant
- 2011-12-20 EP EP22209104.3A patent/EP4159204B1/en active Active
- 2011-12-20 NZ NZ612157A patent/NZ612157A/en unknown
- 2011-12-20 EP EP22209107.6A patent/EP4159205B1/en active Active
- 2011-12-20 BR BR112013015602-3A patent/BR112013015602B1/pt active IP Right Grant
- 2011-12-20 ES ES11849974T patent/ES2820536T3/es active Active
- 2011-12-20 HU HUE22209107A patent/HUE066526T2/hu unknown
- 2011-12-20 WO PCT/US2011/066021 patent/WO2012088033A2/en active Application Filing
- 2011-12-20 ES ES22209107T patent/ES2985024T3/es active Active
- 2011-12-20 CN CN201180066851.0A patent/CN103998041B/zh active Active
- 2011-12-20 LT LTEP11849974.8T patent/LT2654736T/lt unknown
- 2011-12-20 SG SG2013044037A patent/SG191054A1/en unknown
- 2011-12-20 PL PL22209107.6T patent/PL4159205T3/pl unknown
- 2011-12-20 RS RS20240518A patent/RS65496B1/sr unknown
- 2011-12-20 EP EP20179788.3A patent/EP3808343A1/en active Pending
- 2011-12-20 SI SI201131918T patent/SI2654736T1/sl unknown
- 2011-12-20 RS RS20240519A patent/RS65497B1/sr unknown
- 2011-12-20 FI FIEP22209107.6T patent/FI4159205T3/fi active
- 2011-12-20 KR KR1020137019029A patent/KR101911109B1/ko active IP Right Grant
- 2011-12-20 PE PE2013001442A patent/PE20140040A1/es active IP Right Grant
- 2011-12-20 EP EP11849974.8A patent/EP2654736B1/en active Active
- 2011-12-20 AU AU2011349422A patent/AU2011349422B2/en active Active
- 2011-12-20 HR HRP20240563TT patent/HRP20240563T1/hr unknown
- 2011-12-20 PT PT118499748T patent/PT2654736T/pt unknown
- 2011-12-20 DK DK11849974.8T patent/DK2654736T3/da active
- 2011-12-20 MA MA36106A patent/MA34883B1/fr unknown
- 2011-12-20 HU HUE11849974A patent/HUE050788T2/hu unknown
- 2011-12-20 FI FIEP22209104.3T patent/FI4159204T3/fi active
- 2011-12-20 MX MX2013007073A patent/MX2013007073A/es active IP Right Grant
- 2011-12-20 UA UAA201309128A patent/UA113158C2/uk unknown
- 2011-12-20 US US13/330,949 patent/US8580304B2/en active Active
- 2011-12-20 CA CA2822701A patent/CA2822701C/en active Active
- 2011-12-20 PL PL22209104.3T patent/PL4159204T3/pl unknown
- 2011-12-20 JP JP2013546310A patent/JP6126014B2/ja active Active
- 2011-12-20 SI SI201132109T patent/SI4159204T1/sl unknown
- 2011-12-20 DK DK22209107.6T patent/DK4159205T3/da active
- 2011-12-20 EA EA201390913A patent/EA025198B1/ru not_active IP Right Cessation
- 2011-12-20 US US13/991,705 patent/US20130266649A1/en not_active Abandoned
- 2011-12-20 MY MYPI2013701038A patent/MY170501A/en unknown
- 2011-12-20 ES ES22209104T patent/ES2982775T3/es active Active
- 2011-12-20 PT PT222091076T patent/PT4159205T/pt unknown
- 2011-12-20 SI SI201132108T patent/SI4159205T1/sl unknown
- 2011-12-20 HR HRP20240564TT patent/HRP20240564T1/hr unknown
- 2011-12-20 PT PT222091043T patent/PT4159204T/pt unknown
- 2011-12-20 PL PL11849974T patent/PL2654736T3/pl unknown
- 2011-12-20 DK DK22209104.3T patent/DK4159204T3/da active
- 2011-12-20 LT LTEP22209107.6T patent/LT4159205T/lt unknown
- 2011-12-20 HU HUE22209104A patent/HUE066525T2/hu unknown
- 2011-12-20 LT LTEP22209104.3T patent/LT4159204T/lt unknown
2013
- 2013-06-07 ZA ZA2013/04189A patent/ZA201304189B/en unknown
- 2013-06-10 IL IL226855A patent/IL226855A/en active IP Right Grant
- 2013-06-18 DO DO2013000138A patent/DOP2013000138A/es unknown
- 2013-06-18 CL CL2013001779A patent/CL2013001779A1/es unknown
- 2013-07-19 CR CR20130352A patent/CR20130352A/es unknown
- 2013-10-02 US US14/044,139 patent/US9271941B2/en active Active
- 2013-12-11 US US14/103,092 patent/US9399021B2/en active Active
- 2013-12-11 US US14/103,193 patent/US9155706B2/en active Active
2017
- 2017-01-19 JP JP2017007796A patent/JP2017137299A/ja not_active Withdrawn
2020
- 2020-09-03 HR HRP20201409TT patent/HRP20201409T1/hr unknown
- 2020-09-24 CY CY20201100905T patent/CY1123376T1/el unknown
2021
- 2021-05-27 AR ARP210101433A patent/AR122185A2/es unknown

Also Published As

Publication number	Publication date
PT4159204T (pt)	2024-05-07
CN103998041B (zh)	2016-08-17
HRP20240564T1 (hr)	2024-09-27
HUE066526T2 (hu)	2024-08-28
EP2654736A4 (en)	2015-04-22
PT2654736T (pt)	2020-09-24
US20140154316A1 (en)	2014-06-05
US20130266649A1 (en)	2013-10-10
HUE050788T2 (hu)	2021-01-28
PE20140040A1 (es)	2014-02-26
SI4159204T1 (sl)	2024-06-28
TW201249441A (en)	2012-12-16
HUE066525T2 (hu)	2024-08-28
EP4159205A1 (en)	2023-04-05
MA34883B1 (fr)	2014-02-01
AU2011349422A1 (en)	2013-05-02
MY170501A (en)	2019-08-08
SG191054A1 (en)	2013-08-30
DK2654736T3 (da)	2020-09-14
LT4159204T (lt)	2024-05-10
EP4159204B1 (en)	2024-02-14
EP2654736A2 (en)	2013-10-30
BR112013015602B1 (pt)	2022-03-03
HRP20240563T1 (hr)	2024-08-16
FI4159205T3 (fi)	2024-04-23
CY1123376T1 (el)	2021-12-31
ZA201304189B (en)	2014-02-26
JP6126014B2 (ja)	2017-05-10
RS65496B1 (sr)	2024-06-28
AU2011349422B2 (en)	2015-12-10
AR084102A1 (es)	2013-04-24
RS65497B1 (sr)	2024-06-28
SI2654736T1 (sl)	2020-10-30
NZ612157A (en)	2015-05-29
ES2820536T3 (es)	2021-04-21
BR112013015602A2 (pt)	2017-02-21
PL2654736T3 (pl)	2020-12-14
CR20130352A (es)	2013-12-18
US20140037726A1 (en)	2014-02-06
EP3808343A1 (en)	2021-04-21
PL4159204T3 (pl)	2024-07-01
DK4159205T3 (da)	2024-05-13
US20120183613A1 (en)	2012-07-19
DOP2013000138A (es)	2013-11-30
WO2012088033A2 (en)	2012-06-28
MX2013007073A (es)	2013-09-26
TWI505828B (zh)	2015-11-01
EA025198B1 (ru)	2016-11-30
FI4159204T3 (fi)	2024-04-22
US9399021B2 (en)	2016-07-26
CN103998041A (zh)	2014-08-20
PT4159205T (pt)	2024-05-08
CL2013001779A1 (es)	2014-06-27
EP4159205B1 (en)	2024-02-14
EA201390913A1 (ru)	2014-04-30
US8580304B2 (en)	2013-11-12
JP2014510704A (ja)	2014-05-01
ES2982775T3 (es)	2024-10-17
UA113158C2 (xx)	2016-12-26
HRP20201409T1 (hr)	2020-11-27
US20140099365A1 (en)	2014-04-10
AR122185A2 (es)	2022-08-24
LT2654736T (lt)	2020-09-25
IL226855A (en)	2017-04-30
EP4159204A1 (en)	2023-04-05
CA2822701A1 (en)	2012-06-28
US9271941B2 (en)	2016-03-01
LT4159205T (lt)	2024-05-10
WO2012088033A3 (en)	2014-03-13
PL4159205T3 (pl)	2024-06-24
UY33818A (es)	2012-07-31
CA2822701C (en)	2018-10-23
KR20130130028A (ko)	2013-11-29
ES2985024T3 (es)	2024-11-04
JP2017137299A (ja)	2017-08-10
DK4159204T3 (da)	2024-05-21
EP2654736B1 (en)	2020-07-01
SI4159205T1 (sl)	2024-06-28
JO3594B1 (ar)	2020-07-05
US9155706B2 (en)	2015-10-13

Publication	Publication Date	Title
KR101911109B1 (ko)	2018-10-23	신규 제약 조성물
EP3400933A1 (en)	2018-11-14	Novel pharmaceutical trametinib composition
KR20200024890A (ko)	2020-03-09	신규한 약학적 조성물
RU2779429C2 (ru)	2022-09-07	Новая фармацевтическая композиция
AU2014206138A1 (en)	2015-07-23	Combination

Legal Events

Date	Code	Title
2016-07-01	N231	Notification of change of applicant
2016-12-20	A201	Request for examination
2018-03-05	E902	Notification of reason for refusal
2018-09-19	E701	Decision to grant or registration of patent right
2018-10-17	GRNT	Written decision to grant